CureVac denies rumors in coronavirus madness microcosm

18 March 2020

A tidal wave of media speculation involving small German mRNA-based drug specialist CureVac and its management changes, the coronavirus and US President Donald Trump, led the company to hold a media call on Tuesday evening as it could not respond to all the individual reporter inquiries.

Interest in the company had been on the rise ever since Daniel Menichella, then its chief executive, was one of those invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine or treatment by Mr Trump.

Rumors and denials

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK